NTLA-2002

Phase 3Biologic

Intellia Therapeutics

NTLA-2002 is one of 31 biologic programs targeting Hereditary Angioedema. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hereditary AngioedemaActive, not recruiting

Hereditary AngioedemaPhase 3

Active, not recruiting

Competition

Competitive Landscape

43 competitors in Hereditary Angioedema

#DrugCompanyPhaseTrials

Neoral

Crestor

Firazyr

5 4

Lanoxin

Andembry

1 6

Cyklokapron

AAmring

Phase 3

1 7

KALBITOR

Takeda

Phase 3

5 8

C1 Esterase Inhibitor

Takeda

Phase 3

8 9

Dawnzera (autoinjector)

Ionis Pharmaceuticals

Phase 3

6 10

Ruconest

PPharming Technologies B.V.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 3Active, not recruiting

Hereditary Angioedema

NCT06634420

Clinical

Trials by Indication[1]

Hereditary Angioedema1 trial

HAELO: A Phase 3 Study to Evaluate NTLA-2002 in Participants With Hereditary Angioedema (HAE)

Active, not recruiting· Intellia Therapeutics logo

Intellia Therapeutics·Phase 3·NCT06634420·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for NTLA-2002. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NTLA-2002 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NTLA-2002. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Intellia Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: Intellia Therapeutics

NTLA-2002

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Hereditary Angioedema1 trial

References

Drug Info

Quick Facts

Related News